Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


17.09.2018

1 Am J Dermatopathol
2 Ann Surg Oncol
1 Biochem Biophys Res Commun
1 Br J Cancer
1 Br J Dermatol
1 Cancer
2 J Surg Oncol
6 Melanoma Res


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. THOMAS NE, Edmiston SN, Tsai YS, Parker JS, et al
    Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
    Am J Dermatopathol. 2018 Sep 11. doi: 10.1097/DAD.0000000000001259.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. FIELDS AC, Goldberg J, Senturk J, Saadat LV, et al
    Contemporary Surgical Management and Outcomes for Anal Melanoma: A National Cancer Database Analysis.
    Ann Surg Oncol. 2018 Sep 12. pii: 10.1245/s10434-018-6769.
    PubMed     Text format     Abstract available

  3. RAND JG, Faries MB
    Omitting Completion Dissection in Melanoma? Help is Available for Surgeons Coping Without Routine Dissection, But More Work is Needed.
    Ann Surg Oncol. 2018 Sep 12. pii: 10.1245/s10434-018-6744.
    PubMed     Text format    


    Biochem Biophys Res Commun

  4. CHOWDHURY F, Doganay S, Leslie BJ, Singh R, et al
    Cdc42-dependent modulation of rigidity sensing and cell spreading in tumor repopulating cells.
    Biochem Biophys Res Commun. 2018;500:557-563.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. HAMID O, Robert C, Ribas A, Hodi FS, et al
    Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
    Br J Cancer. 2018 Sep 11. pii: 10.1038/s41416-018-0207.
    PubMed     Text format     Abstract available


    Br J Dermatol

  6. XU S, Stump TK, Jain J, Alshurafa N, et al
    Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.
    Br J Dermatol. 2018 Sep 12. doi: 10.1111/bjd.17196.
    PubMed     Text format     Abstract available


    Cancer

  7. GOLDSTEIN AM, Stidd KC, Yang XR, Fraser MC, et al
    Pediatric Melanoma in Melanoma-Prone Families.
    Cancer. 2018 Sep 12. doi: 10.1002/cncr.31641.
    PubMed     Text format     Abstract available


    J Surg Oncol

  8. ISAKSSON K, Nielsen K, Mikiver R, Nieweg OE, et al
    Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.
    J Surg Oncol. 2018 Sep 9. doi: 10.1002/jso.25208.
    PubMed     Text format     Abstract available

  9. KANATSIOS S, Melanoma Project M, Li Wai Suen CSN, Cebon JS, et al
    Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma.
    J Surg Oncol. 2018 Sep 9. doi: 10.1002/jso.25138.
    PubMed     Text format     Abstract available


    Melanoma Res

  10. TINGFENG X, Fuqiang P, Dong L
    Expression and clinical significance of S100 family genes in patients with melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000512.
    PubMed     Text format     Abstract available

  11. TARHINI A, Ghate SR, Ionescu-Ittu R, Manceur AM, et al
    Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000507.
    PubMed     Text format     Abstract available

  12. SHAH S, Luke JJ, Jacene HA, Chen T, et al
    Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000509.
    PubMed     Text format     Abstract available

  13. SEREMET T, Planken S, Schwarze JK, Jansen Y, et al
    Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000501.
    PubMed     Text format     Abstract available

  14. CHRISTENSEN L, Scott J, Bordeaux J
    Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma - compelling but not ready for primetime.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000506.
    PubMed     Text format     Abstract available

  15. DE MELO AC, Wainstein AJA, Buzaid AC, Thuler LCS, et al
    Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years.
    Melanoma Res. 2018 Sep 10. doi: 10.1097/CMR.0000000000000511.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: